* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Thursday, October 23, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    ‘Chainsaw Man — The Movie: Reze Arc’ Review: Hit Manga Gets an Ultra-Violent, Surprisingly Emotional Big-Screen Adaptation – Yahoo

    Chainsaw Man – The Movie: Reze Arc Review: A Brutal and Unexpectedly Emotional Big-Screen Adaptation

    Reba McEntire Details Personal Relationship With Late Stepson Brandon Blackstock – KNDU

    Reba McEntire Shares Emotional Tribute to Her Late Stepson Brandon Blackstock

    Sacramento city leaders approve adding 2 entertainment zones in midtown – CBS News

    Sacramento City Leaders Approve Two Thrilling New Entertainment Zones in Midtown

    AMC brings first new Dolby Experience to Gwinnett since 2017 – Wyoming News Now

    AMC Launches First New Dolby Experience in Gwinnett Since 2017

    Hetzel Design: blending architecture and entertainment – Blooloop

    Hetzel Design: Where Architecture and Entertainment Unite in Perfect Harmony

    Country music legend rushed to hospital year after heart surgery. Here’s what we know – PennLive.com

    Country Music Legend Rushed to Hospital One Year After Heart Surgery – What’s Happening Now?

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Next steps: Technology opens new options for greater mobility – Missouri Independent

    Next Steps: How Technology is Opening Exciting New Doors to Greater Mobility

    Rydberg Technologies Inc. Announces Launch of Rydberg Photonics in Berlin – The Quantum Insider

    Rydberg Technologies Launches Exciting New Photonics Division in Berlin

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 Technology Stocks to Buy Now – Yahoo Finance

    3 Must-Buy Tech Stocks You Can’t Afford to Miss Right Now

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    ‘Chainsaw Man — The Movie: Reze Arc’ Review: Hit Manga Gets an Ultra-Violent, Surprisingly Emotional Big-Screen Adaptation – Yahoo

    Chainsaw Man – The Movie: Reze Arc Review: A Brutal and Unexpectedly Emotional Big-Screen Adaptation

    Reba McEntire Details Personal Relationship With Late Stepson Brandon Blackstock – KNDU

    Reba McEntire Shares Emotional Tribute to Her Late Stepson Brandon Blackstock

    Sacramento city leaders approve adding 2 entertainment zones in midtown – CBS News

    Sacramento City Leaders Approve Two Thrilling New Entertainment Zones in Midtown

    AMC brings first new Dolby Experience to Gwinnett since 2017 – Wyoming News Now

    AMC Launches First New Dolby Experience in Gwinnett Since 2017

    Hetzel Design: blending architecture and entertainment – Blooloop

    Hetzel Design: Where Architecture and Entertainment Unite in Perfect Harmony

    Country music legend rushed to hospital year after heart surgery. Here’s what we know – PennLive.com

    Country Music Legend Rushed to Hospital One Year After Heart Surgery – What’s Happening Now?

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Next steps: Technology opens new options for greater mobility – Missouri Independent

    Next Steps: How Technology is Opening Exciting New Doors to Greater Mobility

    Rydberg Technologies Inc. Announces Launch of Rydberg Photonics in Berlin – The Quantum Insider

    Rydberg Technologies Launches Exciting New Photonics Division in Berlin

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    A look into new technology at Columbia University that could help prevent a dangerous pregnancy complication – ABC7 New York

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    Office Technology: Dealers’ Managed IT Revenue up Nearly 30% – The Cannata Report –

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 E Network Technology Group Limited Closes $1.5 Million Convertible Promissory Note Offering – Quiver Quantitative

    3 Technology Stocks to Buy Now – Yahoo Finance

    3 Must-Buy Tech Stocks You Can’t Afford to Miss Right Now

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Emicizumab Safe, Effective, in Infants With Hemophilia A

December 11, 2023
in Health
Emicizumab Safe, Effective, in Infants With Hemophilia A
Share on FacebookShare on Twitter

SAN DIEGO — Administering emicizumab (Hemlibra) to previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors is effective and safe, according to results from research presented here.

The phase III HAVEN-7 study showed that at a median follow-up of 101.9 weeks, the annualized treated bleeding rate was 0.4 (95% CI 0.30-0.63) among 55 study participants, with 30 children (54.5%) having no treated bleeds, reported Steven Pipe, MD, of the University of Michigan in Ann Arbor.

The annualized bleeding rate for all bleeds was 2.0 (95% CI 1.49–2.66), with no treated spontaneous bleeds.

“This was over a median follow up of over 100 weeks, and the median age was 29 months — so these are totally mobilized toddlers through this clinical cut-off date.” Pipe said during a press briefing at the annual meeting of the American Society of Hematology, “Emicizumab prophylaxis really demonstrated consistent efficacy across all the bleeding endpoints.”

For decades the approach to managing hemophilia has been the use of prophylactic factor VIII protein with factor VIII concentrates. Pipe pointed out this is a challenging process because it requires intravenous infusions frequently because of the short half-life of factor VIII.

Emicizumab is a humanized bispecific monoclonal antibody that bridges factor IX and Factor X to substitute for the function of deficient activated factor VIII, and is approved for the routine prophylaxis of persons with hemophilia A.

However, Pipe observed that infants were underrepresented in studies evaluating emicizumab and so HAVEN-7 was initiated in order to provide more evidence for the prophylactic treatment of this population.

Prophylaxis should be the standard of care for infants with hemophilia A, Pipe suggested, but many don’t start receiving prophylaxis until after their first year of life, mostly due to challenges and complications associated with factor VIII administration, such as venous access issues — including situations in which clinicians have had to rely on central venous access devices.

Emicizumab, on the other hand, can be administered subcutaneously from the time of hemophilia A diagnosis, Pipe explained, “This allows us to meet this treatment gap in the first year of life by enabling very early initiation of prophylaxis, and really may mitigate the risk of untreated or spontaneous traumatic bleeding, which can accrue damage, particularly into joints.”

“Importantly, it could mitigate the risk of intracranial hemorrhages,” Pipe added. “There is a substantial risk of intracranial hemorrhage throughout the first year of life for infants who are not yet on prophylactic therapy.”

He also noted that the study offered the opportunity to look at alterations of the natural history of inhibitor development to factor VIII-containing products, “because we would expect infants to have reduced exposure.”

The 55 participants in the study were all male. Median age at enrollment was 4.0 months, with 45.5% under the age of 3 months, and 54.5% between the age of 3 months and 1 year. All received emicizumab for at least 52 weeks, with a median treatment duration of 100.3 weeks.

Prior to the study, 30 (54.5%) infants were minimally treated (≤5 exposure days), and 25 (45.5%) were previously untreated. Participants received subcutaneous emicizumab 3 mg/kg weekly for 4 weeks, then every 2 weeks for 52 weeks. For the study’s 7-year long-term follow-up, participants could continue on this dosing regimen or switch to either 1.5 mg/kg weekly or 6 mg/kg every 4 weeks.

Overall, 207 bleeds (treated or untreated) were reported in 46 participants (83.6%), while 42 treated bleeds, all traumatic, were reported in 25 participants (45.5%). None of the children had>3 treated bleeds, 37 (67.3%) had 0-3 bleeds, and 9 (16.4%) had no bleeds. Two participants had>10 bleeds, all untreated, and none in joint/muscle.

Pipe said no new safety signals were identified, no participants developed anti-drug antibodies directed against emicizumab, and the factor VIII exposure rates were low.

Treatment-related adverse events occurred in 9 patients and all were grade 1 injection site reactions, typically redness or irritation. No adverse events led to withdrawals, dose modifications, or interruptions, “Importantly no intracranial hemorrhages were reported in this cohort,” Pipe said.

Pipe reported that all 55 participants were evaluable for immunogenicity in order to show they had no anti-drug antibodies to emicizumab, and that in about half (28) there was at least one factor VIII exposure. Following factor VIII exposure, 24 participants were evaluated for a factor VIII inhibitor; only two tested positive.

“So this is quite a low rate, but it is related to the really infrequent exposures to factor VIII,” Pipe said. “What’s notable about emicizumab is that its efficacy is not impacted by the appearance of a factor VIII inhibitor, so that patients can continue on prophylaxis with emicizumab, and the two children who tested positive for factor VIII inhibitors have continued on with emicizumab.”

author['full_name']

Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Disclosures

HAVEN-7 was sponsored by Hoffmann-La Roche.

Pipe reported relationships with Takeda, Sanofi, Roche/Genentech, Regeneron/Intellia, Pfizer, Novo Nordisk, LFB, Freeline, HEMA Biologics, GenVentiv, Equilibra Bioscience, CSL Behring, BioMarin, Bayer, ASC Therapeutics, ApcinteX, Spark Therapeutics, uniQure.

Primary Source

American Society of Hematology

Source Reference: Pipe S, et al “Emicizumab prophylaxis in infants with severe hemophilia A without factor VIII Inhibitors: results from the primary analysis of the HAVEN 7 study” ASH 2023; Abstract 505.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/ashhematology/107778

Tags: EffectiveEmicizumabhealth
Previous Post

Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer

Next Post

‘New Gold Standard’ for Previously Untreated CLL

Former world chess champion Vladimir Kramnik investigated for bullying following death of grandmaster Daniel Naroditsky – CNN

Former World Chess Champion Vladimir Kramnik Under Investigation Amid Tragic Loss of Grandmaster Daniel Naroditsky

October 23, 2025
Trump approval on economy hits new low: Quinnipiac poll – The Hill

Trump’s Economic Approval Hits Historic Low in Shocking New Poll

October 23, 2025
‘Chainsaw Man — The Movie: Reze Arc’ Review: Hit Manga Gets an Ultra-Violent, Surprisingly Emotional Big-Screen Adaptation – Yahoo

Chainsaw Man – The Movie: Reze Arc Review: A Brutal and Unexpectedly Emotional Big-Screen Adaptation

October 23, 2025
WHO launches new country guidance for health emergency coordination – World Health Organization (WHO)

WHO Launches Bold New Global Guidelines to Revolutionize Health Emergency Coordination

October 23, 2025
Gettysburg suffers damage as advocates ask public to be vigilant during shutdown – CNN

Gettysburg Endures Damage as Advocates Call for Public Vigilance Amid Shutdown

October 23, 2025
Vibrio pectenicida strain FHCF-3 is a causative agent of sea star wasting disease – Nature

Vibrio pectenicida strain FHCF-3 is a causative agent of sea star wasting disease – Nature

October 23, 2025
Condensation defying gravity – European Space Agency

Condensation defying gravity – European Space Agency

October 23, 2025
Guest educators bring fun environmental science to Kent middle school – MyEasternShoreMD

Guest Educators Ignite Passion for Environmental Science at Kent Middle School

October 23, 2025
Equity Lifestyle Properties, Inc. Profit Rises In Q3, Beats Estimates – Nasdaq

Equity Lifestyle Properties Delivers Impressive Q3 Profit, Exceeding All Expectations

October 23, 2025
Next steps: Technology opens new options for greater mobility – Missouri Independent

Next Steps: How Technology is Opening Exciting New Doors to Greater Mobility

October 23, 2025

Categories

Archives

October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Sep    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (882)
  • Economy (904)
  • Entertainment (21,775)
  • General (17,762)
  • Health (9,945)
  • Lifestyle (916)
  • News (22,149)
  • People (904)
  • Politics (914)
  • Science (16,114)
  • Sports (21,403)
  • Technology (15,883)
  • World (887)

Recent News

Former world chess champion Vladimir Kramnik investigated for bullying following death of grandmaster Daniel Naroditsky – CNN

Former World Chess Champion Vladimir Kramnik Under Investigation Amid Tragic Loss of Grandmaster Daniel Naroditsky

October 23, 2025
Trump approval on economy hits new low: Quinnipiac poll – The Hill

Trump’s Economic Approval Hits Historic Low in Shocking New Poll

October 23, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version